Insider Selling: Artiva Biotherapeutics (NASDAQ:ARTV) CEO Sells $168,933.60 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) CEO Fred Aslan sold 23,463 shares of the stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $7.20, for a total transaction of $168,933.60. Following the completion of the sale, the chief executive officer directly owned 1,519,606 shares in the company, valued at approximately $10,941,163.20. This represents a 1.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Fred Aslan also recently made the following trade(s):

• On Monday, October 5th, Fred Aslan sold 61,696 shares of Artiva Biotherapeutics stock. The stock was sold at an average price of $6.84, for a total transaction of $422,000.64.
• On Tuesday, September 8th, Fred Aslan sold 23,429 shares of Artiva Biotherapeutics stock. The shares were sold at an average price of $10.92, for a total transaction of $255,844.68.

Artiva Biotherapeutics Price Performance

Artiva Biotherapeutics stock opened at $6.94 on Friday. Artiva Biotherapeutics, Inc. has a 1-year low of $2.71 and a 1-year high of $14.53. The firm has a market capitalization of $339.30 million, a P/E ratio of -2.10 and a beta of 2.40. The company’s 50-day moving average is $9.83 and its 200 day moving average is $9.23.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.63). Research analysts anticipate that Artiva Biotherapeutics, Inc. will post -2.62 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Squarepoint Ops LLC bought a new stake in Artiva Biotherapeutics during the 2nd quarter valued at $144,000. Spark Investment Management LLC purchased a new position in shares of Artiva Biotherapeutics during the second quarter valued at $160,000. Alyeska Investment Group L.P. increased its stake in shares of Artiva Biotherapeutics by 173.6% during the second quarter. Alyeska Investment Group L.P. now owns 273,615 shares of the company’s stock valued at $2,654,000 after buying an additional 173,615 shares during the period. Nantahala Capital Management LLC bought a new stake in shares of Artiva Biotherapeutics in the second quarter valued at about $2,910,000. Finally, 5AM Venture Management LLC bought a new stake in shares of Artiva Biotherapeutics in the second quarter valued at about $22,827,049.

Wall Street Analyst Weigh In

Several brokerages have commented on ARTV. Wall Street Zen raised Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Cantor Fitzgerald reissued an “overweight” rating and set a $40.00 target price on shares of Artiva Biotherapeutics in a research note on Friday, October 2nd. HC Wainwright restated a “buy” rating on shares of Artiva Biotherapeutics in a report on Friday, October 2nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, July 21st. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $39.00.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc (NASDAQ:ARTV) is a clinical-stage biotechnology company developing allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s approach is designed to produce off-the-shelf cell therapies that can be manufactured at scale and administered without using cells collected from each individual patient.

Artiva’s lead investigational product, AlloNK, also known as AB-101, is an allogeneic NK cell therapy being evaluated in combination with rituximab for autoimmune conditions, including systemic lupus erythematosus and lupus nephritis.